<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04547439</url>
  </required_header>
  <id_info>
    <org_study_id>2020-1052</org_study_id>
    <nct_id>NCT04547439</nct_id>
  </id_info>
  <brief_title>Sleep, Diabetic Retinopathy and Melatonin</brief_title>
  <official_title>Sleep and Circadian Regulation in Diabetic Retinopathy: The Role of Intrinsically Photosensitive Retinal Ganglion Cells and Melatonin Supplementation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Illinois at Chicago</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Chicago</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Illinois at Chicago</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study explores the use of melatonin in patients with diabetic retinopathy&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized controlled study using melatonin for 8 weeks in patients with diabetic&#xD;
      retinopathy on outcomes of sleep and circadian regulation&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 3, 2021</start_date>
  <completion_date type="Anticipated">June 2026</completion_date>
  <primary_completion_date type="Anticipated">December 2025</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Double blinded randomized controlled study</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
    <masking_description>Participants and investigators are blinded.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Sleep pattern</measure>
    <time_frame>14 days</time_frame>
    <description>Sleep pattern: Sleep duration and sleep efficiency will be assessed by wrist actigraphy, to be worn by the participants for 14 days</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Melatonin and Cortisol Rhythm</measure>
    <time_frame>24 hours</time_frame>
    <description>Melatonin and cortisol pattern (peak times of the levels, dim light melatonin onset) will be assessed from 24 hour blood sampling</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">36</enrollment>
  <condition>Diabetes Mellitus</condition>
  <condition>Diabetic Retinopathy</condition>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Melatonin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Melatonin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Melatonin</intervention_name>
    <description>Melatonin 3 mg will be taken nightly for 8 weeks</description>
    <arm_group_label>Melatonin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo will be given nightly for 8 weeks</description>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Type 2 diabetes (clinically diagnosed, taking anti-diabetes medications or history of&#xD;
             elevated A1C≥6.5%)&#xD;
&#xD;
          -  40-65 years of age&#xD;
&#xD;
          -  Diabetic retinopathy of at least moderate degree&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  use of melatonin&#xD;
&#xD;
          -  antidepressants or antipsychotics&#xD;
&#xD;
          -  illicit drug use&#xD;
&#xD;
          -  night shift work or travel beyond 2 time zones in the month before enrollment&#xD;
&#xD;
          -  end stage renal disease requiring renal replacement therapy&#xD;
&#xD;
          -  history of stroke or transient ischemic attacks&#xD;
&#xD;
          -  history of dementia or memory impairment&#xD;
&#xD;
          -  uncontrolled congestive heart failure or recent hospitalization for cardiac condition&#xD;
             (6 months)&#xD;
&#xD;
          -  chronic obstructive pulmonary disease requiring oxygen&#xD;
&#xD;
          -  severe chronic liver disease such as cirrhosis&#xD;
&#xD;
          -  ongoing treatment for major medical problems such as cancer&#xD;
&#xD;
          -  history of severe hypoglycemia defined as hypoglycemic episodes requiring assistance&#xD;
             from others within the past six months.&#xD;
&#xD;
          -  Significant depressive symptoms&#xD;
&#xD;
          -  untreated severe OSA (AHI≥ 30 events/hour),&#xD;
&#xD;
          -  uncontrolled hypertension (blood pressure ≥ 160/100 mmHg),&#xD;
&#xD;
          -  uncontrolled diabetes (A1C ≥ 11%),&#xD;
&#xD;
          -  abnormal TSH&#xD;
&#xD;
          -  abnormal liver function (AST or ALT&gt;3x upper limits of normal&#xD;
&#xD;
          -  use of sedatives and hypnotics.&#xD;
&#xD;
          -  clinically significant epiretinal membranes, clinically significant lens opacities, or&#xD;
             cystoid macular edema, iris neovascularization, iris atrophy, or an asymmetrically&#xD;
             shaped pupil, nuclear sclerotic, posterior subcapsular, or cortical lens opacities&#xD;
             greater than 2+, a history of pan-retinal photocoagulation.&#xD;
&#xD;
          -  hemoglobin &lt;11.5 g/dL in women and &lt;13.5 g/dL in men.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Sirimon Reutrakul</last_name>
    <phone>3129966060</phone>
    <email>sreutrak@uic.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Illinois at Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sirimon Reutrakul, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Brzezinski A, Vangel MG, Wurtman RJ, Norrie G, Zhdanova I, Ben-Shushan A, Ford I. Effects of exogenous melatonin on sleep: a meta-analysis. Sleep Med Rev. 2005 Feb;9(1):41-50.</citation>
    <PMID>15649737</PMID>
  </reference>
  <reference>
    <citation>Singer C, Tractenberg RE, Kaye J, Schafer K, Gamst A, Grundman M, Thomas R, Thal LJ; Alzheimer's Disease Cooperative Study. A multicenter, placebo-controlled trial of melatonin for sleep disturbance in Alzheimer's disease. Sleep. 2003 Nov 1;26(7):893-901.</citation>
    <PMID>14655926</PMID>
  </reference>
  <reference>
    <citation>Garfinkel D, Laudon M, Nof D, Zisapel N. Improvement of sleep quality in elderly people by controlled-release melatonin. Lancet. 1995 Aug 26;346(8974):541-4.</citation>
    <PMID>7658780</PMID>
  </reference>
  <reference>
    <citation>Raygan F, Ostadmohammadi V, Bahmani F, Reiter RJ, Asemi Z. Melatonin administration lowers biomarkers of oxidative stress and cardio-metabolic risk in type 2 diabetic patients with coronary heart disease: A randomized, double-blind, placebo-controlled trial. Clin Nutr. 2019 Feb;38(1):191-196. doi: 10.1016/j.clnu.2017.12.004. Epub 2017 Dec 12.</citation>
    <PMID>29275919</PMID>
  </reference>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>June 27, 2020</study_first_submitted>
  <study_first_submitted_qc>September 7, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 14, 2020</study_first_posted>
  <last_update_submitted>April 26, 2021</last_update_submitted>
  <last_update_submitted_qc>April 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Illinois at Chicago</investigator_affiliation>
    <investigator_full_name>Sirimon Reutrakul</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Retinal Diseases</mesh_term>
    <mesh_term>Diabetic Retinopathy</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melatonin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

